Revance Therapeutics (RVNC) Reports Complete Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Revance Therapeutics (RVNC) Tops Q3 EPS by 2c
November 4, 2019 4:38 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.96), $0.02 better than the analyst estimate of ($0.98).
Revance is entering a pivotal period, given the large number of value-inflection points we have created for the company, beginning in just a few weeks with the anticipated submission of our first BLA for DAXI with the FDA, said Mark J. Foley, President and Chief... More
Revance Therapeutics (RVNC) Reports Publication of SAKURA 1 & SAKURA 2 Results in Plastic and Reconstructive Surgery
November 4, 2019 8:11 AM ESTRevance Therapeutics, Inc. (NASDAQ: RVNC) today announced the publication of results from the Phase 3 studies, SAKURA 1 and SAKURA 2, in Plastic and Reconstructive Surgery (PRS), the peer reviewed Journal of the American Society of Plastic Surgeons. These two Phase 3 studies evaluated Revances long-acting neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), for the treatment of moderate and severe glabellar lines.
This manuscript presents the findings from SAKURA 1 and 2 side-by-side, which demonstrate the consistency of efficacy and safety results evident between the two pivotal studies, as well as the reproducibility of these... More
